1. De Vita V. T., Hellman S., Rosenberg S. A.
Cáncer de pulmón. Principios y Práctica de Oncología, 1997; vol. 1, 30: 849-950.
2. López J..J., Colomer R. Cáncer de pulmón y mediastino.
Oncología Médica 1999; Tomo 1, 7: 405-484.
3. Rosell R. Cáncer de pulmón. Documentos de Consenso
Oncología, 1999.
4. Summaries on treatment of nonsmall cell lung cancer and
small cell lung cancer for health professionals. National Cancer Institute.
5. Hoffman P. C., Mauer A. M., Vokes E. E. Lung Cancer. Lancet
2000; 355: 479-85.
6. Greenlee R.T., Murray T., Bolden S., Wingo P. A. Cancer
Statistics, 2000. CA Cancer J Clin 2000; 50: 7-33.
7. McKean-Cowdin R., Spencer H., Ross R. R. Declining Cancer
Rates in the 1990s. J Clin Oncol, 2000; 18:2258-2268.
8. Sugarbaker D.J., Strauss G. M. Advances in surgical staging
and therapy of non-small-cell lung cancer. Seminars in Oncology, 1993; 20:163-172.
9. Davila D., Williams D. The etiology of lung cancer. Mayo
Clin Proc 1993; 68: 170-182.
10. Shaw GL: Screening for lung cancer. En: Johnson BE Y
Johnson DH (eds.): Lung Cancer. New York: Wiley-Liss Inc, 1995; 55-72.
11. Rosell R., Gómez Codina J., Camps C. A randomized trial
comparing preoperative chemotherapy plus surgery with surgery alone in patients with
non-small cell lung cancer. N Engl J Med 1994; 330: 153-158.
12. Non-small Cell Lung Cancer Collaborative Group.
Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on
individual patients from 52 randomised clinical trials. British Medical Journal 311
(7010): 899-909, 1995.
13. PORT Meta-analysis Trialists Group. Postoperative
radiotherapy in non-small-cell lung cancer: systematic reviw and meta-analysis of
individual patient data from nine randomised controlled trials. Lancet, 1998; 352:
257-262.
14. Huisman C., Smit E. F., Giaccone G. Second line
chemotherapy in relapsing or refractory non-small-cell lung cancer: a review. Journal of
Clinical Oncology, 2000; 18: 3722-3730.
15. Sandler A. B., Nemunaitis J., Denham C. Phase III trial of
Gemcitabine plus Cisplatin versus Cisplatin alone in patients with locally advanced or
metastatic non-small-cell lung cancer. Journal of Clinical Oncology 2000; 18 (1): 122-130.
16. Turrisi A. T. III, Kim K., Blum R. Twice-daily compared
with once-daily thoracic radiotherapy in limited small-cell lun cancer treated
concurrently with cisplatin and etoposide. New England Journal of Medicine 1999; 340 (4);
265-271.
17. Evans W. K., Shepherd F. A., Feld R. VP-16 and Cisplatin as
first line therapy in small-cell lung cancer. Journal of Clinical Oncology 1985; 3 (11):
1471-1477.
18. Greco F. A. Treatment options for patients with relapsed
small-cell lung cancer. Lung Cancer 1993; 9 (Suppl. 1): 985-989.
19. Wang K.P., Haponik E.F., Britt E.J. Transbronchial needle
aspiration of peripheral pulmonary nodules. Chest 1984; 86: 819-823.
20. Bartsch H., Ptruzzelli S., Deflora S. Carcinogen metabolism
in human lung tissues and the effect of tobacco smoking: results from case control
multicenter study on lung cancer patients. Environ Health Perspec, 1992; 98: 119-124.
